Moleculin Biotech, Inc. (MBRX)

NASDAQ: MBRX · Real-Time Price · USD
2.450
-0.100 (-3.92%)
Nov 4, 2024, 4:00 PM EST - Market closed
-3.92%
Market Cap 6.97M
Revenue (ttm) n/a
Net Income (ttm) -25.17M
Shares Out 2.84M
EPS (ttm) -11.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 29,607
Open 2.650
Previous Close 2.550
Day's Range 2.360 - 2.650
52-Week Range 0.400 - 6.240
Beta 1.86
Analysts Strong Buy
Price Target 35.00 (+1,328.57%)
Earnings Date Nov 15, 2024

About MBRX

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription fact... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 2, 2016
Employees 18
Stock Exchange NASDAQ
Ticker Symbol MBRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for MBRX stock is "Strong Buy." The 12-month stock price forecast is $35.0, which is an increase of 1,328.57% from the latest price.

Price Target
$35.0
(1,328.57% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Strong preclinical evidence of Annamycin's potential for treating pancreatic cancer presented at AACR expands collaboration HOUSTON , Nov. 4, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MB...

18 hours ago - PRNewsWire

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

Access the transcript here HOUSTON , Oct. 17, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late stage pharmaceutical company with a broad portfolio of...

18 days ago - PRNewsWire

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

Live webcast discussion featuring internationally renowned Acute Myeloid Leukemia (AML) Key Opinion Leaders Ongoing progress of pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed ...

4 weeks ago - PRNewsWire

Moleculin to Present at Two Upcoming Investor Conferences

HOUSTON , Oct. 4, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late stage pharmaceutical company with a broad portfolio of drug candidates targeting h...

4 weeks ago - PRNewsWire

Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma

Data recently presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer Treatment with Annamycin results in statistically significant inhibit...

6 weeks ago - PRNewsWire

Moleculin Participates in Virtual Investor "What this Means" Segment

Wally Klemp, CEO of Moleculin, discusses the Company's recent update on the Phase 2 clinical trial of STAT3 inhibitor in combination with radiation for the treatment of glioblastoma Watch the "What Th...

7 weeks ago - PRNewsWire

Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

– Investigator-initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin – Funding for study provided by NIH and BrainUp® – Trial combines WP1066 and radiatio...

2 months ago - PRNewsWire

Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference

HOUSTON , Sept. 3, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a Phase 3 clinical stage pharmaceutical company with a broad portfolio of drug candidate...

2 months ago - PRNewsWire

Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Live webcast on Wednesday, August 28 th at 3:40 PM ET HOUSTON , Aug. 26, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a Phase 3 clinical stage pharmaceu...

2 months ago - PRNewsWire

Moleculin Announces Closing of up to $16.5 Million Public Offering

$5.5 million financing upfront with up to an additional $11.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants HOUSTON , Aug. 19, 2024 /PRNewswire/ ...

2 months ago - PRNewsWire

Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update

-         Positive outcome from End of Phase 1B/2 Meeting with FDA -         Company proceeding with a pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possible accelerated ...

2 months ago - PRNewsWire

Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET

HOUSTON , Aug. 5, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), Phase 3 clinical stage pharmaceutical company with a broad portfolio of drug candidates t...

3 months ago - PRNewsWire

Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial

Based on an encouraging discussion in the End of Phase 1B/2 Meeting with FDA the Company plans to: Proceed with a pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possible a...

3 months ago - PRNewsWire

Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML

HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates target...

4 months ago - PRNewsWire

Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

– 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations  – Current median durability of response (mDOR) of CRc's = 6 months and increasing (n=9)  – In 2nd line subjects (n=10)...

5 months ago - PRNewsWire

Moleculin to Present at the Virtual Investor Pitch Conference

Live video webcast on Tuesday, June 18 th at 3:00 PM ET HOUSTON , June 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical ...

5 months ago - PRNewsWire

Moleculin to Participate in the Virtual Investor Lunch Break Series

Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Wednesday, June 12 th at 12:00 PM ET  HOUSTON , June 5, 2024 /PRNewswire/ --  Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Molecul...

5 months ago - PRNewsWire

Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress

HOUSTON , May 16, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti...

6 months ago - PRNewsWire

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

– Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin – Trial combines WP1066 and radiation, which demonstrated both significant therapeuti...

6 months ago - PRNewsWire

Moleculin Biotech, Inc. (MBRX) Q1 2024 Earnings Call Transcript

Moleculin Biotech, Inc. [MBRX] Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Walter Klemp - Chairman and CEO Jonathan Foster - EVP and CFO Paul Waymack - Senior CMO Jen...

6 months ago - Seeking Alpha

Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update

–     Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=1...

6 months ago - PRNewsWire

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin

Patent, once issued, will provide composition protection through 2040, with potential for additional term extension Annamycin is advancing towards pivotal AML study in 2024 and may qualify for an acce...

6 months ago - PRNewsWire

Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast

HOUSTON , May 8, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin...

6 months ago - PRNewsWire

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13) Full MB-106 trial reaches 20 subjects with CRc of 45% in 1st – 7th line, wi...

6 months ago - PRNewsWire

Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024

Live video webcast roundtable with members from the Moleculin Management Team and Dr. Tallman to discuss the unmet medical needs in the treatment of acute myeloid leukemia (AML), Annamycin and the Com...

6 months ago - PRNewsWire